In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.

However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.

Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.

After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.

ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.